Le Lézard
Classified in: Health, Business
Subjects: NPT, CHI, TDS, LEG, AVO, FVT, DEI

Allergy & Asthma Day Capitol Hill on May 3 to Spotlight Patient Access to Safe, Affordable Medications


FAIRFAX, Va., April 27, 2023 /PRNewswire/ -- How to ensure asthma and allergy patients get the medications they need when they need it? Allergy & Asthma Network is urging Congress to pass legislation that helps ensure the more than 26 million Americans with asthma and 50+ million with allergies have access to safe, effective and affordable medical care.

On May 3, the Network is hosting its 26th annual Allergy & Asthma Day Capitol Hill (AADCH) in Washington, DC. Our theme is "Moving Toward Patient-Centered Care." Two bipartisan bills currently before Congress address patient-centered care in different ways:

In addition to the Safe Step Act and the HELP Copays Act, Allergy & Asthma Network is also asking Congress to support two bills that impact schoolchildren:

During AADCH, patients, families, advocates, healthcare professionals and industry partners go to Capitol Hill to meet with federal legislators and their staff. The goal is to raise awareness and urge passage of legislation that ends needless death and suffering due to asthma, allergies and related conditions.

This year, Allergy & Asthma Network has once again scheduled in-person visits with members of Congress, their staff and policymakers. Nearly 100 AADCH advocates are expected to come to Capitol Hill on May 3.

The Network will also host its annual Congressional Lunch Briefing on May 3 in the Rayburn House Office Building in Washington, DC. The briefing features the Congressional Asthma & Allergy Caucus, presentations from leading allergists, the National Medical Association, the National Institutes of Health (NIH) and the U.S. Environmental Protection Agency (EPA), and patient testimonials.

"We're excited to head back to Capitol Hill to advocate for patient-centered care and urge Congress to enact legislation and health policies that puts the needs of patients first," says Allergy & Asthma Network interim CEO Lynda Mitchell, MA, CAE. "We will advocate to expand access to high-quality affordable care, including for schoolchildren living with asthma and severe allergies. We will also promote evidence-based care and greater expansion of telehealth services."

Allergy & Asthma Network also advocates for federal funding to support ongoing asthma and allergy health programs at the U.S. Centers for Disease Control and Prevention (CDC), National Institutes of Health and the U.S. Environmental Protection Agency (EPA), among others.

For a complete list of AADCH issues and priorities, visit our Advocacy Center.

Advocates not able to attend AADCH in person can participate by sending emails to their legislators on May 3. Our Take Action webpage lists all active campaigns that need your support. You will find template emails to send to your legislators, making advocating as easy as just a few clicks.

"Whether it's in person or virtually, the more advocates who connect with their legislators, the more powerful our voice and the greater our impact," Mitchell says. "We will share our message that expanding access to care helps patients get the treatment they need to better manage their condition ? and live a full, active life."

About Allergy & Asthma Network

Allergy & Asthma Network is the leading nonprofit patient outreach, education, advocacy and research organization for people with asthma, allergies and related conditions. Our patient-centered network unites patients, families, caregivers, health professionals, industry partners and government decision makers to improve health and quality of life for all people with asthma and allergies. We specialize in making medically accurate health information understandable to all while promoting evidence-based standards of care. Learn more at AllergyAsthmaNetwork.org.

Contact: Gary Fitzgerald
Allergy & Asthma Network
703-641-9595
[email protected]

SOURCE Allergy & Asthma Network


These press releases may also interest you

at 21:07
Fellow Aurinia Shareholders, ILJIN SNT Co., Ltd. and its affiliates (collectively, "ILJIN") is a long-term holder of more than 5% of Aurinia Pharmaceuticals Inc. ("Aurinia" or the "Company") and has been supportive of the Company's mission since 2010...

at 20:51
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune, ophthalmology and other major...

at 20:30
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. and Alvotech , today announced the availability of SIMLANDI (adalimumab-ryvk) injection in the U.S., as an interchangeable biosimilar to Humira for the treatment of adult...

at 20:05
CUPID is a Phase I safety and dosimetry study of TLX592, Telix's investigational antibody-based targeted alpha therapy for prostate cancer.Establishes proof-of-concept for Telix's proprietary RADmAb® engineered antibody platform, currently under...

at 19:42
The shareholders in Immunovia AB (publ), Reg. No. 556730-4299, are hereby invited to the Annual General Meeting ("AGM") to be held at The Spark, Scheeletorget 1, Medicon Village, in Lund on Wednesday 19 June 2024 at 10 a.m. CEST. Right to...

at 18:54
The Board of Directors of Immunovia AB (publ) ("Immunovia" or the "Company") has today,...



News published on and distributed by: